PMID- 8428340
OWN - NLM
STAT- MEDLINE
DCOM- 19930308
LR  - 20190620
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 71
IP  - 3 Suppl
DP  - 1993 Feb 1
TI  - Transgenic models for the study of prostate cancer.
PG  - 1165-71
AB  - Transgenic model systems provide tools for obtaining information that clarifies 
      important relationships between genetic alterations and carcinogenesis. One such 
      relationship is the induction of specific growth factor activities by dominantly 
      acting oncogenes. Using a "transgenic organ" model referred to as mouse prostate 
      reconstitution (MPR) under conditions where the ras and myc oncogenes were 
      introduced using a recombinant retrovirus into both the mesenchymal and 
      epithelial compartments of the urogenital sinus, poorly differentiated prostate 
      cancer (PC) was produced with high frequency (> 90%) in inbred C57BL/6 mice. 
      Time-course studies using northern blotting and immunohistochemical analysis 
      showed that the transition from benign to malignant status invariably was 
      associated with the induction of elevated transforming growth factor-beta 1 
      (TGF-beta 1) expression. Additional immunohistochemical analysis of TGF-beta 1 in 
      human PC and benign prostatic hyperplasia (BPH) showed that positive 
      extracellular staining was significantly more extensive in PC compared with BPH. 
      This differential staining pattern was evident in focal areas of PC adjacent to 
      BPH. These findings in both the MPR model system and human PC suggest that 
      elevated TGF-beta 1 expression is involved in the progression to malignancy and 
      that its pattern of expression may become a useful marker of PC. Additional 
      studies using transgenic animal models will continue to provide important 
      clinically useful information about PC in man.
FAU - Thompson, T C
AU  - Thompson TC
AD  - Scott Department of Urology, Baylor College Medicine, Houston, Texas 77030.
FAU - Truong, L D
AU  - Truong LD
FAU - Timme, T L
AU  - Timme TL
FAU - Kadmon, D
AU  - Kadmon D
FAU - McCune, B K
AU  - McCune BK
FAU - Flanders, K C
AU  - Flanders KC
FAU - Scardino, P T
AU  - Scardino PT
FAU - Park, S H
AU  - Park SH
LA  - eng
GR  - CA50588/CA/NCI NIH HHS/United States
GR  - DK43523/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Transforming Growth Factor beta)
SB  - IM
GS  - gp-91-phox
GS  - int-2
GS  - myc
GS  - ras
MH  - Animals
MH  - *Disease Models, Animal
MH  - Genes, myc
MH  - Genes, ras
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - *Mice, Transgenic/genetics
MH  - *Prostatic Neoplasms/genetics
MH  - Transforming Growth Factor beta/genetics/*metabolism
RF  - 45
EDAT- 1993/02/01 00:00
MHDA- 1993/02/01 00:01
CRDT- 1993/02/01 00:00
PHST- 1993/02/01 00:00 [pubmed]
PHST- 1993/02/01 00:01 [medline]
PHST- 1993/02/01 00:00 [entrez]
AID - 10.1002/1097-0142(19930201)71:3+<1165::aid-cncr2820711440>3.0.co;2-u [doi]
PST - ppublish
SO  - Cancer. 1993 Feb 1;71(3 Suppl):1165-71. doi: 
      10.1002/1097-0142(19930201)71:3+<1165::aid-cncr2820711440>3.0.co;2-u.